Zosano Pharma (NASDAQ:ZSAN) released its earnings results on Wednesday. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.02), MarketWatch Earnings reports.
Shares of ZSAN stock opened at $0.49 on Friday. The stock has a market cap of $33.61 million, a price-to-earnings ratio of -0.35 and a beta of 2.98. The business’s fifty day moving average is $0.54 and its 200 day moving average is $1.00. Zosano Pharma has a twelve month low of $0.33 and a twelve month high of $1.97.
ZSAN has been the topic of a number of analyst reports. HC Wainwright decreased their price target on Zosano Pharma from $4.00 to $2.50 and set a “buy” rating on the stock in a research note on Friday, October 2nd. Zacks Investment Research raised Zosano Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 14th. BTIG Research reduced their target price on Zosano Pharma from $7.00 to $2.00 and set a “buy” rating on the stock in a research note on Thursday, October 22nd. Finally, Maxim Group reissued a “buy” rating and set a $2.00 target price on shares of Zosano Pharma in a research note on Friday, October 2nd. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $1.88.
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its intracutaneous microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the treatment of migraine.
Recommended Story: What is the float in trading stocks?
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.